To provide you with a better experience, our website uses cookies. To continue browsing, you please accept our cookies policy.

J'accepte

Cookies informations

Our site uses tools, such as cookies, to analyse and improve your experience. You can unsubscribe from these follow-ups:

Statistics

Nous utilisons des outils, tels que Google Analytics, pour suivre le trafic Web et vérifier l'efficacité de notre site.

Essential

Cookies requis pour les services essentiels et les fonctionnalités telles que les formulaires de connexion, l'intégration du panier et le contrôle d'accès. Sans eux, notre site Web ne peut pas fonctionner correctement et nous ne pouvons fournir aucun service. La désactivation n'est pas disponible.

These parameters will be stored for 24 hours

Excellence
for life

Excellence dedicated to nuclear medicine,
healthcare and environment.

More about us

Our departments

One group, two entities

IRE, world leader in the production of radioisotopes and its prevention division, IRE Lab

IRE ELiT Radiopharma, a laboratory of ideas and actions for radiopharmaceutical innovation

Our figures

Our figures

IRE is one of the leaders in the production of molybdenum (99Mo) for the manufacture of technetium-99m (99mTc) generators.

IRE ELiT is one of the only two global suppliers of germanium-68 (68Ge) / gallium-68 (68Ga) generators to have been approved as a drug in Europe and as an Active Pharmaceutical Ingredient in the United States.

Our history
7MPatients

Can benefit from a medical examination each year thanks to radioisotopes produced at IRE

100MTurnoveren 2019
230Employees including
30 at IRE ELiT
15%Of turnover
reinvested in R&D

Our
values

The values of our company are the moral principles we set for ourselves in the performance of our activities. They shape our corporate culture.

25-02-2022
The fight against cancer intensified thanks to SCK CEN and the IRE

SCK CEN, the Belgian Nuclear Research Centre, and the National Institute for Radioelements (IRE) are going to start the large-scale production of lutetium-177. This decision, validated today by the signature of the two partners, opens up opportunities for cancer patients. Among other things, this radioisotope is very promising for the treatment of prostate cancer. This type of cancer is responsible for 90,000 deaths each year in Europe.

22-02-2022
SMART takes critical step towards the production of medical isotope Mo-99 without uranium

Fleurus, 22 February 2022 – Since 2018, the National Institute for Radioelements (IRE) has been working with the Dutch company ASML on the SMART project. Its goal: to develop a new technology to produce a radioisotope that is crucial to nuclear medicine, without using uranium. February 2022 marks a turning point in the future of this ambitious project since a proof of concept test has recently validated the main principles of this unprecedented technology. This is a major step in the design and engineering phase, the success of which will allow confirmation of technical choices during 2022 in preparation for the Board of Directors’ decision regarding investment in an industrial facility.

01-02-2022
First commercial deliveries of I-131 based on LEU from IRE plant

Fleurus, Belgium 1st February 2021 - IRE is pleased to announce that its first commercial deliveries of I-131 based on the irradiation of Low Enriched Uranium (LEU) targets have started this week.

26-08-2021
IRE ELiT submitted Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for the 100 mCi Ge68/Ga68 Galli Eo® generator.

Cardinal Health (NYSE: CAH) and IRE ELiT (the radiopharmaceutical subsidiary of IRE Group) are working to expand patient access to novel radiopharmaceuticals for Positron Emission Tomography (PET) imaging as demand in the United States (U.S.) continues to grow. Cardinal Health is the preferred U.S. distributor of the IRE ELiT 100 mCi Germanium-68/Gallium-68 radionuclide generator (Ge-68/Ga-68 Galli Eo® generator) in support of clinical investigational trials, pre-commercial research and post-approval commercial sales in the U.S. and its territories, including Puerto Rico.

09-02-2021
IRE submits its request for a single permit for the construction of a 100% Walloon cyclotron

In 2020, IRE signed a contract with IBA to build a cyclotron on its site in Fleurus. This state-of-the-art equipment will enable the IRE to produce Germanium-68 locally, a key raw material to enable the institute to contribute even more to the fight against cancer. The IRE is pursuing the progress of this project by submitting today an application for a single permit (urban planning and environmental permit).